Search results for "double-blind"

showing 10 items of 662 documents

Metabolic effect of berberine-silymarin association: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials.

2019

The aim of this study is to assess the impact of a combination of berberine and silymarin on serum lipids and fasting plasma glucose (FPG) through a systematic review of literature and meta-analysis of the available randomized, double-blind, placebo-controlled clinical trials (RCTs). A systematic literature search in SCOPUS, PubMed-Medline, ISI Web of Science, and Google Scholar databases was conducted up to October 2, 2018, in order to identify RCTs assessing changes in plasma concentrations of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and FPG during treatment with berberine and silymarin in combina…

Blood Glucosemedicine.medical_specialtysilymarinReviewsBlood lipidsberberine; cholesterol; fasting plasma glucose; meta-analysis; nutraceutical; silymarin; Berberine; Blood Glucose; Double-Blind Method; Fasting; Humans; Lipids; Randomized Controlled Trials as Topic; SilymarinReviewPlaceboGastroenterologymeta-analysiDouble blind03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBerberineDouble-Blind MethodInternal medicineberberineMedicineHumansfasting plasma glucoseRandomized Controlled Trials as TopicPharmacology0303 health sciencesbusiness.industryCholesterolData synthesis030302 biochemistry & molecular biologycholesterolFastingLipidsClinical trialmeta-analysischemistrymeta‐analysis030220 oncology & carcinogenesisMetabolic effectsMeta-analysisnutraceuticalCardiology and Cardiovascular Medicinebusiness
researchProduct

A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: Re…

2006

Clinical studies have demonstrated beneficial effects for clopidogrel in patients with atherothrombotic disease. Recent in vitro studies identified stimulating effects of clopidogrel on endothelial cells, pointing towards mechanisms of action beyond the inhibition of platelet aggregation. We hypothesized that in vivo use of clopidogrel improves endothelial dysfunction in patients with coronary artery disease (CAD). Fifty-eight patients with CAD were randomly assigned to double-blinded oral administration of one single dose of clopidogrel 300 mg (C300) or 600 mg (C600), respectively. Endothelial function was assessed by measurement of flow-mediated dilation (FMD) of the brachial artery befor…

Blood PlateletsMalemedicine.medical_specialtyTiclopidineCoronary Artery DiseaseLoading doseCoronary artery diseaseP2Y12Double-Blind MethodSuperoxidesmedicine.arteryInternal medicinePurinergic P2 Receptor AntagonistsHumansMedicinePlateletcardiovascular diseasesBrachial arteryEndothelial dysfunctionAgedbusiness.industryVascular diseaseMicrofilament ProteinsMiddle AgedPhosphoproteinsmedicine.diseaseClopidogrelReceptors Purinergic P2Y12ClopidogrelAnesthesiaCardiologyFemaleEndothelium VascularCardiology and Cardiovascular MedicinebusinessCell Adhesion MoleculesDilatation Pathologiccirculatory and respiratory physiologymedicine.drugAtherosclerosis
researchProduct

Budesonide/formoterol maintenance and reliever therapy: a new treatment approach for adult patients with asthma.

2007

An inhaled corticosteroid (ICS) or an ICS/long-acting beta(2)-agonist (LABA) combination plus short-acting beta(2)-agonist (SABA) as needed for symptom relief is recommended for persistent asthma. Additionally, budesonide/formoterol maintenance and reliever therapy (Symbicort SMART, AstraZeneca, Sweden) has been approved for adults in the European Union. This option is well tolerated and offers greater reductions in asthma exacerbations together with similar improvements in daily symptom control, at a lower overall steroid load, compared with fixed-dose ICS/LABA plus SABA.Two large clinical trials investigated the use of budesonide/formoterol as maintenance and reliever compared with medium…

BudesonideAdultMalemedicine.medical_specialtyAdolescentlaw.inventionPlacebosRandomized controlled trialDouble-Blind MethodlawInternal medicineFormoterol Fumaratemedicinemedia_common.cataloged_instanceHumansAnti-Asthmatic AgentsEuropean unionBudesonidemedia_commonAsthmaAgedRandomized Controlled Trials as TopicAged 80 and overbusiness.industryGeneral MedicineAdrenergic beta-AgonistsMiddle Agedmedicine.diseaseClinical trialTreatment OutcomeBudesonide/formoterolEthanolaminesPhysical therapyFormoterol FumarateDrug Therapy CombinationFemaleFormoterolbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugCurrent medical research and opinion
researchProduct

Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis.

2010

Autoimmune hepatitis (AIH) is a chronic liver disease associated with cirrhosis and liver failure. Corticosteroid therapy induces long-term remission but has many side effects. We compared the effects of budesonide (a steroid that is rapidly metabolized, with low systemic exposure) and prednisone, both in combination with azathioprine.We performed a 6-month, prospective, double-blind, randomized, active-controlled, multicenter, phase IIb trial of patients with AIH without evidence of cirrhosis who were given budesonide (3 mg, three times daily or twice daily) or prednisone (40 mg/d, tapered to 10 mg/d); patients also received azathioprine (1-2 mg/kg/d). Treatment was followed by a 6-month, …

BudesonideAdultMalemedicine.medical_specialtyCirrhosisAdolescentAzathioprineAutoimmune hepatitisChronic liver diseaseGastroenterology03 medical and health sciences0302 clinical medicineHLA-DR3 AntigenDouble-Blind MethodPrednisoneInternal medicineMedicineHumansProspective StudiesBudesonideChildAgedHepatitisIntention-to-treat analysisHepatologybusiness.industryGastroenterologyMiddle Agedmedicine.disease3. Good healthHepatitis AutoimmuneEndocrinology030220 oncology & carcinogenesisPrednisone030211 gastroenterology & hepatologyFemalebusinessmedicine.drugGastroenterology
researchProduct

Regular versus as-needed budesonide and formoterol combination treatment for moderate asthma: A non-inferiority, randomised, double-blind clinical tr…

2015

Summary Background Treatment guidelines for patients with moderate persistent asthma recommend regular therapy with a combination of an inhaled corticosteroid and a longacting β 2 agonist plus as-needed rapid-acting bronchodilators. We investigated whether symptom-driven budesonide and formoterol combination therapy administered as needed would be as effective as regular treatment with this combination plus as-needed symptom-driven terbutaline for patients with moderate asthma. Methods In this non-inferiority randomised clinical trial, we recruited adult patients (18–65 years of age) with stable moderate persistent asthma, according to 2006 Global Initiative for Asthma guidelines. Patients …

BudesonideMalePediatricsKaplan-Meier Estimatelaw.inventionRandomized controlled triallawMedicineOutpatient clinicBudesonide Formoterol Fumarate Drug CombinationAnti-Asthmatic AgentsTreatment Failureeducation.field_of_studyasthma; clinical trialMedicine (all)clinical trialMiddle AgedCombined Modality TherapyBronchodilator AgentsFemalemedicine.drugHumanAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentTerbutalinePopulationSettore MED/10 - Malattie Dell'Apparato RespiratorioPlaceboDrug Administration ScheduleNOYoung AdultDouble-Blind MethodAdministration InhalationTerbutalineinhaled corticosteroids LABA asthma clinical trialHumansAnti-Asthmatic AgenteducationBronchodilator AgentPulmonary and Respiratory Medicine; Medicine (all)AsthmaAgedPulmonary and Respiratory Medicine RCT asthmabusiness.industryComputerSystemsOrganization_COMPUTER-COMMUNICATIONNETWORKSmedicine.diseaseAsthmarespiratory tract diseasesFormoterolbusiness
researchProduct

Randomized, Double-Blind, Clinically Controlled Trial of Intranasal Calcitonin Treatment in Patients with Hip Fracture

2002

The objective of this study was to evaluate the short-term outcome of intranasal calcitonin treatment of elderly hip fracture patients on pain, bone loss, functional recovery, and length of hospital stay. In addition, we wanted to compare the effect of calcitonin with placebo on fusion of hip fractures treated with internal fixation using a screw or a nail. In a randomized, double-blind, clinically controlled trial, 260 independently living patients (aged 65 years or older) with acute hip fracture were randomly assigned to intranasal calcitonin 200 IU daily for 3 months or matching placebo nasal spray. Analyses were completed on an intention-to-treat basis. Three months after the operation,…

CalcitoninMalemedicine.medical_specialtyVisual analogue scaleEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosisPainPlacebolaw.inventionFracture Fixation InternalEndocrinologyDouble-Blind MethodRandomized controlled trialBone DensitylawActivities of Daily LivingFracture fixationmedicineHumansInternal fixationOrthopedics and Sports MedicineBone ResorptionAdministration IntranasalOsteoporosis PostmenopausalAgedPain MeasurementAged 80 and overFracture HealingHip fractureHip Fracturesbusiness.industryLength of Staymedicine.diseaseSurgeryCalcitoninFemalebusinessCalcified Tissue International
researchProduct

Improved inter-observer agreement of an expert review panel in an oncology treatment trial--Insights from a structured interventional process.

2015

Abstract Purpose Oncologic imaging is a key for successful cancer treatment. While the quality assurance (QA) of image acquisition protocols has already been focussed, QA of reading and reporting offers still room for improvement. The latter was addressed in the context of a prospective multicentre trial on fluoro-deoxyglucose (FDG)–positron-emission tomography (PET)/CT-based chemoradiotherapy for locally advanced non-small cell lung cancer (NSCLC). Material and methods An expert panel was prospectively installed performing blinded reviews of mediastinal NSCLC involvement in FDG–PET/CT. Due to a high initial reporting inter-observer disagreement, the independent data monitoring committee (I…

Cancer Researchmedicine.medical_specialtyLung NeoplasmsContext (language use)Sensitivity and SpecificityDouble-Blind MethodFluorodeoxyglucose F18Carcinoma Non-Small-Cell LungOutcome Assessment Health CaremedicineData monitoring committeeHumansMedical physicsObserver VariationPET-CTmedicine.diagnostic_testbusiness.industryReproducibility of ResultsChemoradiotherapyClinical trialOncologyPositron emission tomographyPositron-Emission TomographyRadiologybusinessTomography X-Ray ComputedQuality assuranceKappaChemoradiotherapyEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Genistein supplementation and cardiac function in postmenopausal women with metabolic syndrome: Results from a pilot strain-echo study

2017

Genistein, a soy-derived isoflavone, may improve cardiovascular risk profile in postmenopausal women with metabolic syndrome (MetS), but few literature data on its cardiac effects in humans are available. The aim of this sub-study of a randomized double-blind case-control study was to analyze the effect on cardiac function of one-year genistein dietary supplementation in 22 post-menopausal patients with MetS. Participants received 54 mg/day of genistein (n = 11) or placebo (n = 11) in combination with a Mediterranean-style diet and regular exercise. Left ventricular (LV) systolic function was assessed as the primary endpoint, according to conventional and strain-echocardiography measurement…

Cardiac function curvemedicine.medical_specialtycardiac function; echocardiography; genistein; menopause; metabolic syndromegenistein; metabolic syndrome; menopause; cardiac function; echocardiographyGenisteinlcsh:TX341-641030204 cardiovascular system & hematologyPlaceboArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodInterquartile rangeInternal medicinemedicineHumans030212 general & internal medicineEnd-systolic volumeBody surface areaNutrition and DieteticsEjection fractionbusiness.industryCardiac functionHeartMiddle Agedmedicine.diseaseGenisteinMetabolic syndromePostmenopauseEndocrinologychemistryEchocardiographyDietary SupplementsCardiologyCardiac function; Echocardiography; Genistein; Menopause; Metabolic syndrome; Food ScienceFemaleMetabolic syndromeMenopausebusinesslcsh:Nutrition. Foods and food supplyFood Science
researchProduct

Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, str…

2003

Background: the effects of long-term administration of β-blockers on left ventricular (LV) function during exercise in patients with ischemic heart disease (IHD) and idiopathic dilated cardiomyopathy (DCM) are controversial. Patients and methods: patients with stable congestive heart failure (CHF) (New York heart association [NYHA] class II and III) and ejection fraction (EF) ≤0.40 were randomized to metoprolol, 50 mg t.i.d. or placebo for 6 months. Patients were divided into two groups: ischemic heart disease (IHD) and idiopathic dilated cardiomyopathy (DCM). The mean EF was 0.29 in both groups and 92% were taking angiotensin-converting enzyme (ACE) inhibitors. In the IHD group, 84% had su…

Cardiomyopathy DilatedMalemedicine.medical_specialtyTime FactorsAdrenergic beta-AntagonistsMyocardial IschemiaCardiomyopathyRadionuclide angiographyDouble-Blind MethodInternal medicineIdiopathic dilated cardiomyopathymedicineHumanscardiovascular diseasesMyocardial infarctionExerciseMetoprololEjection fractionVentricular Remodelingmedicine.diagnostic_testbusiness.industryMitral Valve InsufficiencyGated Blood-Pool ImagingHeartStroke VolumeAtrial fibrillationMiddle Agedmedicine.diseaseHeart failureExercise TestCardiologyFemaleCardiology and Cardiovascular MedicinebusinessMetoprololmedicine.drugEuropean Journal of Heart Failure
researchProduct

Comparison of heparin to citrate as a catheter locking solution for non-tunneled central venous hemodialysis catheters in patients requiring renal re…

2014

Background The incidence of acute kidney injury (AKI) is estimated at 10 to 20% in patients admitted to intensive care units (ICU) and often requires renal replacement therapy (RRT). ICU mortality in AKI patients can exceed 50%. Venous catheters are the preferred vascular access method for AKI patients requiring RRT, but carry a risk of catheter thrombosis or infection. Catheter lock solutions are commonly used to prevent such complications. Heparin and citrate locks are both widely used for tunneled, long-term catheters, but few studies have compared citrate versus heparin for patients with short-term, non-tunneled catheters. We aim to compare citrate 4% catheter lock solution versus hepar…

Catheter Obstructionmedicine.medical_specialtyCatheterization Central VenousTime Factorsmedicine.medical_treatmentHemodialysis CatheterCatheter ObstructionMedicine (miscellaneous)urologic and male genital diseasesHospitals UniversityStudy ProtocolAcute renal failureClinical ProtocolsDouble-Blind MethodRenal DialysisCitrate lockIntensive careUpper Extremity Deep Vein ThrombosisProhibitinsmedicineCentral Venous CathetersHumansPharmacology (medical)Heparin lockRenal replacement therapyCitratesProspective StudiesContraindicationbusiness.industryHeparinAcute kidney injuryAnticoagulantsEquipment DesignAcute Kidney Injurymedicine.diseasefemale genital diseases and pregnancy complicationsSurgeryCatheterIntensive Care UnitsTreatment OutcomeResearch DesignHemodialysisHemodialysisFranceCritically ill patientbusinessCatheter lockTrials
researchProduct